Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Entresto’s potential first-mover advantage in largely untapped HFpEF market could be extremely lucrative for Novartis

A positive recommendation from an FDA Advisory Committee has set Novartis’ Entresto (sacubitril/valsartan) on track to become the first drug to be approved for the treatment of heart failure with preserved ejection fraction (HFpEF). The potential label expansion could prove to be extremely lucrative for Novartis, providing the company with a first-mover advantage in this […]
Read more

NovoNordisk’s Rybelsus a game changer in T2D but may face a tough road ahead as it strides into Alzheimer’s space

NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer‘s disease may allow the company to secure its position in yet another lucrative market. However, while this drug will benefit from being the first-to-market oral GLP-1RA in T2D space and capture a […]
Read more

Renal denervation market demonstrates tremendous opportunity following FDA breakthrough device designation

SoniVie and ReCor Medical both recently received US Food and Drug Administration (FDA) breakthrough device designation for their TIVUS and Paradise renal denervation systems. With few manufacturers in the field and a market opportunity of almost 10 million hypertensive patients each year, the breakthrough designation puts ReCor Medical and SoniVie far ahead of larger manufacturers […]
Read more

COVID-19 has left a third of areas in America with limited ICU capacity

The growing rate of new COVID-19 cases indicates the US is facing a major crisis of hospital shortages not yet seen in this pandemic, and there is an expected near-doubling of hospitalizations and intensive care unit (ICU) admissions before year’s end, says GlobalData, a leading data and analytics company. Topias Lemetyinen, Pharma Analyst at GlobalData, […]
Read more

COVID-19 deals boost South Korea’s pharmaceutical industry growth

South Korea’s pharmaceutical sector is becoming increasingly innovative and attractive to foreign investment only 18 months into the government’s $1.7bn five-year biotech plan. The country’s pharmaceutical industry is now poised to grow further due to its preparations to manufacture large amounts of COVID-19 vaccines for domestic and foreign markets, says GlobalData, a leading data and […]
Read more

Roche’s Ocrevus set to top $7.6bn in sales by 2028, backed by new dosing approval in the MS market

Following the news that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS); Sarah Elsayed, MBA, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Ocrevus boasts a superior pharmacological profile in the MS market due to its high efficacy, good tolerability and convenient six-month dosing regimen via intravenous infusion (IV). The new FDA approval will further improve […]
Read more

JDRF’s T1Detect population screening could revolutionize type 1 diabetes awareness and management

Juvenile Diabetes Research Foundation (JDRF) recently announced the launch of its ground-breaking screening initiative for type 1 diabetes (T1D), T1Detect, which aims to make early detection of T1D easier and more accessible to the broader population. This initiative will revolutionize awareness and management of the disease going forward as it will open up the market for preventative therapeutics and other disease-modifying therapies, says GlobalData, a leading data and analytics company. Samisha Khangaonkar, Pharma Analyst at GlobalData, comments: “Approximately 85% […]
Read more

Established players in Japan’s immunology market dominate branded digital marketing space, finds GlobalData

The Japanese immunology market is highly competitive with many innovator products available for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn’s disease (CD), and ankylosing spondylitis (AS) indications. Across these indications, the branded support available for initially approved therapies dominate the digital marketing space compared […]
Read more

COVID-19 expedites India’s focus on innovation within pharma, says GlobalData

The COVID-19 pandemic has pushed India to expedite focus on pharma research and development (R&D) to become more independent. The hope of getting indigenous COVID-19 vaccines has boosted the government’s confidence towards indigenous research and development and this momentum should continue, says GlobalData, a leading data analytics and research company. India is expected to unveil a […]
Read more

AbbVie’s Rinvoq tops defending champion Dupixent in atopic dermatitis

The recently demonstrated superiority of AbbVie’s Rinvoq (upadacitinib) versus Regeneron and Sanofi’s Dupixent (dupilumab) across primary and all secondary endpoints in the Phase IIIb Heads Up study may well showcase its potential to usurp Dupixent as the gold standard of atopic dermatitis (AD) therapy, but it is the speed of which the efficacy became evident in patients that shows the drug’s real promise, says GlobalData, a leading data and […]
Read more

US cannot wait on vaccines to control COVID-19

Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally; Kasey Fu, Director of Epidemiology at GlobalData, a leading data and analytics company, offers her view: “News that the US has hit another […]
Read more

Slovakia’s national COVID-19 testing program was only a temporary solution

Following Slovakia’s national testing program from 31 October – 1 November, where two-thirds of the population were tested and the number of new daily cases dropped substantially, Slovakia was applauded for its efforts and held up as a possible solution to other European countries, says GlobalData, a leading data and analytics company. Katie Wrenn, Pharma Analyst at GlobalData, comments: “The recent weeks have seen a slight rise in new cases, and though this increase is minimal, if cases continue […]
Read more

Immune checkpoint inhibitors will represent 47% of the 5EU gastric and gastroesophageal market by 2029

The lack of approved immune checkpoint inhibitors (ICI) in the gastric and gastroesophageal adenocarcinoma (G/GEJAC) market in the *5EU is expected to significantly enhance the revenue of Opdivo and Keytruda following their upcoming label expansions. In fact, GlobalData’s latest report, ‘Gastric and Gastroesophageal Junction Adenocarcinoma Global Drug Forecast and Market Analysis to 2029’, notes that these […]
Read more

The US has the largest number of late-stage COVID-19 vaccines in development

With Pfizer/BioNTech’s COVID-19 vaccine becoming the first mRNA vaccine in the world to receive emergency use approval by the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA), the race is on for other bio/pharma companies with COVID-19 candidates to seek out authorization from regulators within the coming weeks, says GlobalData, a leading data and analytics company. Sharon Cartic at GlobalData comments: “The US has the largest number of COVID-19 vaccines in late-stage clinical development among the top pipeline geographies, with the EU following closely behind. The US currently has a total of 12 COVID-19 vaccines in Phases II and III, […]
Read more

Galapagos Phase IIA PINTA IPF topline study results are cause for cautious optimism

Galapagos recently reported positive topline results from its Phase IIA PINTA clinical trial investigating the use of 100 mg GLPG1205 for the treatment of idiopathic pulmonary fibrosis (IPF). Although the trial had a promising result in a disease with high unmet clinical need, the real test for the drug will come in the form of larger trials and subsequent statistical evaluation, according to GlobalData a leading data […]
Read more
1 … 72 73 74 75 76 … 108